Mission Bio, a leader in single-cell multiomic solutions for precision medicine, appoints Brian Kim as its new CEO, leveraging his extensive experience in life sciences. Kim’s successful track record includes leading companies like Fortis Life Sciences and driving expansion at LGC Biosearch Technologies. His strategic vision aligns with Mission Bio’s goal to advance single-cell multiomics into clinical applications, signaling a transformative phase for the company in revolutionizing personalized medicine.
What You Should Know:
– Mission Bio, a pioneer in single-cell multiomic solutions for precision medicine, announced today the appointment of Brian Kim as its new Chief Executive Officer.
– Kim brings over two decades of life sciences expertise and a proven track record of driving growth and innovation to the company, poised to propel Mission Bio’s technology into clinical applications.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Brian Kim Bio/Background
Kim’s career boasts a series of successes in the life sciences sphere, showcasing his ability to navigate complex markets and build high-growth companies:
- Fortis Life Sciences: Founded and led the company to become a leading provider of proprietary reagents for clinical customers.
- LGC Biosearch Technologies: Spearheaded the division’s expansion into diagnostics and therapeutics, culminating in a successful sale in 2020.
- PerkinElmer’s Life Science and Tools: Revitalized product innovation, revamped the commercial organization, and reignited business growth.
Stuart Essig, PhD, Chairman of the Board at Mission Bio, highlights Kim’s impeccable alignment with the company’s vision: “Brian’s experience in life sciences tools commercialization and clinical end markets perfectly aligns with our mission to advance single-cell multiomics into translational research and clinical applications. He joins us at a pivotal moment when our Tapestri platform is demonstrating tangible progress in improving patient health outcomes.”
A New Chapter for Single-Cell Multiomics:
With Brian Kim at the helm, Mission Bio is poised to capitalize on the growing potential of single-cell multiomics. His leadership and expertise will be instrumental in translating this innovative technology from the lab to the clinic, paving the way for a future of personalized medicine that benefits patients worldwide.
Source: Hit Consultant